Head-to-head evidence
Bepranemab vs Etalanetug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
Bepranemab
Developed by UCB
NCT04867616 · Phase 2 · completed
The study randomized 466 participants to two bepranemab dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was change in CDR-SB at Week 80, but whether this endpoint was met cannot be determined because results are not posted.
Etalanetug
Developed by Eisai
NCT04971733 · Phase 1/2 · completed
The study treated 8 participants with E2814 in open-label, single-arm cohorts without randomization, blinding, or a comparator, and its biomarker primary endpoint was not a controlled clinical comparison. Because the named drug is Etalanetug but the trial intervention was E2814, these results are not direct evidence for Etalanetug.
Next expected readout: December 2026 · NCT06602258 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bepranemab's landscape · Etalanetug's landscape